Cytokinetics To Present Non-Clinical Data on CK-1827452 at the 2005 Annual Heart Failure Society of America Meeting
South San Francisco, CA - September 12, 2005
Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that non-clinical data for CK-1827452, a novel small molecule activator of cardiac myosin, will be presented at the 2005 Annual Heart Failure Society of America (HFSA) Meeting in Boca Raton, Florida. The moderated oral poster presentation will highlight data relating to the mechanism of action of CK-1827452 as well as its characterization in a heart failure model in animals, data that supported the recent initiation of a Phase I clinical trial for this drug candidate. CK-1827452 is the first clinical drug candidate to arise from the company’s cardiac myosin activator program, an effort that leverages Cytokinetics’ expertise in cytoskeletal pharmacology and muscle contractility.
Poster Presentation and Discussion at HFSA M
The abstract related to this presentation is currently available through the HFSA website (www.hfsa.org). The poster will be presented at the HFSA meeting as follows:
Abstract # 017: Direct Activation of Cardiac Myosin by CK-1827452 Improves Cardiac Function in a Dog Heart Failure Model. (Poster displayed on Monday, September 19, 2005, 9:00 AM – 7:00 PM ET and Moderated Poster Presentation, 5:45 PM – 6:45 PM ET; moderated by Fady Malik, M.D., Ph.D., F.A.C.C., Director, Cardiovascular Programs, Cytokinetics.)
Status of CK-1827452 Development
Cytokinetics recently announced that CK-1827452 had entered a Phase I clinical trial. This first-in-humans Phase I clinical trial is a double-blind, randomized, placebo-controlled, dose-escalation study being conducted to investigate the safety, tolerability, pharmacokinetic, and pharmacodynamic profile of CK-1827452 in normal, healthy volunteers. The trial is designed to identify the maximum tolerated dose of a 6-hour intravenous infusion of CK-1827452. The effect of CK-1827452 on the left ventricular function of these healthy volunteers will be evaluated using serial echocardiograms. The cross-over design of this clinical trial will ensure that patients will act as their own controls to compare the effects of escalating doses of CK-1827452 to those of placebo. The clinical trial is being conducted under a Clinical Trial Application (CTA) at a clinical investigative center in the United Kingdom.
About Cytokinetics
Cytokinetics is a leading biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that specifically target the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Cytokinetics’ focus on the cytoskeleton enables it to develop novel and potentially safer and more effective classes of drugs directed at treatments for cancer, cardiovascular disease and other diseases. Cytokinetics has developed a cell biology driven approach and proprietary technologies to evaluate the function of many interacting proteins in the complex environment of the intact human cell. Cytokinetics employs the PUMA™ system and Cytometrix™ technologies to enable early identification and automated prioritization of compounds that are highly selective for their intended protein targets without other cellular effects, and may therefore be less likely to give rise to clinical side effects. Cytokinetics and GlaxoSmithKline have entered into a strategic alliance to discover, develop and commercialize small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases. GlaxoSmithKline is conducting Phase II and Phase Ib clinical trials for ispinesib (SB-715992) and a Phase I clinical trial for SB-743921, each a drug candidate that has emerged from the strategic alliance. Cytokinetics’ heart failure program is the second program to leverage the company’s expertise in cytoskeletal pharmacology. Cytokinetics recently initiated a Phase I human clinical trial with CK-1827452, a novel small molecule cardiac myosin activator, for the treatment of heart failure. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements relating to our clinical research and development program, including presentations of pre-clinical data and statements regarding the potential benefits of our drug candidates and potential drug candidates and the enabling capabilities of our proprietary technologies. Such statements are based on management’s current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval (including the risks relating to uncertainty of patent protection for Cytokinetics’ intellectual property or trade secrets, Cytokinetics’ ability to obtain additional financing if necessary and unanticipated research and development and other costs). For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.
